Despite the advancement of modern medicine, many promising and innovative medicinal approaches are currently limited by issues related to drug delivery and the serious side-effects that often accompany them. These issues may include systemic toxicity, absorption issues, poor intracellular delivery and tissue penetration challenges, among others. A naturally targeted, LNC drug delivery platform offers the potential to address these shortcomings by creating a vehicle that can deliver a range of powerful, but otherwise compromised therapeutics in ways that overcome their innate limitations and unlock the potential to create and deliver life-changing medicines to patients.

Matinas BioPharma's differentiated LNC drug delivery platform has far greater flexibility than other lipid nano-particle approaches and offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, oligonucleotides, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies. The Company's lead asset, MAT2203 is currently in Phase 2 development as an FDA designated Qualified Infectious Disease Product for the initial indication for the prevention of invasive fungal infections in patients with Acute Lymphoblastic Leukemia.

Based on preclinical and clinical data validation with MAT2203, the Company plans to extend the utility of its proprietary LNC platform in partnership with pharmaceutical and biotech companies with therapeutic strategies that can be enhanced or enabled by utilizing Matinas' advanced LNC technology.